Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012
Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012
Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions
Neurol 78:1655-1662, Abou Zeid, N.,et al, 2012
"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Cogan Syndrome An Analysis of Reported Neurological Manifestations
The Neurologist 18:55-63, Antonios,N. and Silliman,S., 2012
Neuromyelitis Optica and Pregnancy
Neurol 78:875-879, Bourre,B.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
Inflammatory Cortical Demyelination in Early Sclerosis
NEJM 365:2188-2197, Lucchinetti, C.F.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Clinicopathologic Conference, Cystoisospora Belli Enteritis and HIV Infection
NEJM 365:2306-2316, Case 38-2011, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011
When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011
Clinical and Functional Outcome and Factors Predicting Prognosis in Osmotic Demyelination Syndrome (Central Pontine and/or Extrapontine Myelinolysis) in 25 Patients
JNNP 82:326-331, Kallakatta,R.N.,et al, 2011
Prior Suggestive Symptoms in One-Third of Patients Consulting for a "First" Demyelinating Event
JNNP 82:323-325, Gout,O.,et al, 2011
Spectrum of Paraneoplastic Disease Associated With Lymphoma
Neurol 76:705-710, Briani,C.,et al, 2011
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
A Clinical Prediction Rule for Ambulation Outcomes After Traumatic Spinal Cord Injury: A Longitudinal Cohort Study
Lancet 377:1004-1010, 972, van Middendorp,J.J,et al, 2011
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
Spinal Muscular Atrophy A Timely Review
Arch Neurol 68:979-984, Kolb, S.J.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
Syndrome of Inappropriate Antidiuresis May Herald or Accompany Neuromyelitis Optica
Neurol 77:1644-1645, Iorio, R.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Yellow Fever Vaccination and Increased Relapse Rate in Travelers with Multiple Sclerosis
Arch Neurol 68:1267-1271, Farez, M.F. and Correale, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
A Strange Case of Waitress Headache
Lancet 378:1824, Libera, D.D.,et al, 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Paraneoplastic isolated myelopathy Clinical course and neuroimaging clues
Neurol 76:2089-2095, Flanagan, E.P.,et al, 2011
Predicting motor outcome and death in term hypoxic-ischemic encephalopathy
Neurol 76:2055-2061, Martinez-Biarge, M.,et al, 2011
Sustained motion perception deficit following optic neuritis Behavioral and cortical evidence
Neurol 76:2103-2111, Raz, N.,et al, 2011
Disability, distress and unemployment in neurology outpatients with symptoms unexplained by organic disease
JNNP 82:810-813, 710, Carson, A.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011